Clinical trials: Consolidation
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial is studying the side effects of giving azacitidine together with gemtuzumab ozogamicin to see how well it works in treating older patients with previously untreated acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia
- Trial name
- NCT00658814
- Testing
- Azacitidine, Gemtuzumab Ozogamicin
- Where
- 177 sites in United States
- Volunteers
- 133 people
- Sponsor
- National Cancer Institute (NCI)
Speech, Consolidation
Sensory Basis of Speech Motor Learning
These studies test the hypothesis that sensory areas of the brain participate in the consolidation of speech motor memory by using transcranial magnetic stimulation to suppress activity in somatosensory and auditory cortex…
- Trial name
- NCT04497428
- Testing
- Adaptation, cTBS
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yale University
Neuroblastoma
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer. Antibodies are made by the body to attack tumors and to fight infections.
- Trial name
- NCT01183429
- Testing
- 3F8 and 13-cis-retinoic acid
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myelodysplastic Syndromes
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar trihydrochloride, a modulator of multidrug resistance (MDR), may help daunorubicin and cytarabine…
- Trial name
- NCT00046930
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- 92 sites in United States, Israel
- Volunteers
- 449 people
- Sponsor
- Eastern Cooperative Oncology Group
Prostate Cancer
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer.
- Trial name
- NCT00024167
- Testing
- Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium
- Where
- 40 sites in United States
- Volunteers
- 265 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258362
- Testing
- carboplatin, docetaxel, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01706666
- Testing
- bortezomib, cyclophosphamide, lenalidomide
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if clofarabine given in combination with cytarabine and decitabine can help to control the disease in patients with AML or MDS who are 60 years old or older.
- Trial name
- NCT00778375
- Testing
- Clofarabine, Cytarabine, Decitabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Ganglioneuroblastoma, Stage 1 Neuroblastoma
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread.
- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma
- Trial name
- NCT01798004
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin
- Where
- 123 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00979212
- Testing
- panitumumab, carboplatin, paclitaxel
- Where
- 31 sites in United States
- Volunteers
- 71 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer, Radiation Toxicity
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel, carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00533949
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- 213 sites in United States, Canada
- Volunteers
- 544 people
- Sponsor
- Radiation Therapy Oncology Group
Refractory Plasma Cell Myeloma
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
This phase II trial studies how well giving bortezomib, lenalidomide, and dexamethasone together works in treating patients with multiple myeloma undergoing stem cell transplant.
- Trial name
- NCT02353468
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Leukemia
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with newly…
- Trial name
- NCT00509093
- Testing
- imatinib mesylate, gene expression analysis, mutation analysis
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma
Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00059839
- Testing
- doxorubicin hydrochloride, mercaptopurine, methotrexate
- Where
- 159 sites in United States, Australia and 3 more
- Volunteers
- 129 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF).
- Trial name
- NCT03033303
- Testing
- Hu3F8, GM-CSF, Isotretinoin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
This study is for patients with newly diagnosed or relapsed multiple myeloma. The main purpose of this study is to see how their disease responds to consolidation treatment (treatment aimed at further decreasing cancer cells)…
- Trial name
- NCT00135200
- Testing
- Iodine I 131 Tositumomab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lymphoma, Mantle Cell Lymphoma
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
- Trial name
- NCT01415752
- Testing
- rituximab, Bendamustine, bortezomib
- Where
- 418 sites in United States, Canada
- Volunteers
- 373 people
- Sponsor
- Eastern Cooperative Oncology Group
Carcinoma, Non-Small-Cell Lung
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA…
- Trial name
- NCT02343952
- Testing
- Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 93 people
- Sponsor
- Nasser Hanna, M.D.
Multiple Myeloma
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
- Trial name
- NCT04436029
- Testing
- Descartes 11
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cartesian Therapeutics
B-cell Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
This phase II trial is studying how well giving fludarabine together with rituximab followed by alemtuzumab works in treating patients with chronic lymphocytic leukemia.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia
- Trial name
- NCT00098670
- Testing
- alemtuzumab, rituximab, fludarabine phosphate
- Where
- 2 sites in United States
- Volunteers
- 102 people
- Sponsor
- National Cancer Institute (NCI)